Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Stenocare

1,60 DKK

-5,33 %

Mindre end 1K følgere

STENO

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-5,33 %
+1,59 %
+24,03 %
+264,46 %
+120,35 %
+48,42 %
-70,65 %
-79,74 %
-88,28 %

Stenocare er aktiv i sundhedsbranchen. Virksomheden har specialiseret sig i udviklingen af ​​medicinsk cannabis. Stenocare er en af ​​de første spillere, der er begyndt at sælge medicinske cannabisolier i Danmark. I fremtiden vil virksomheden også vende sig til andre europæiske markeder med sit produktsortiment. Stenocares har sit hovedkontor med beliggenhed i Randers.

Læs mere
Markedsværdi
69,45 mio. DKK
Aktieomsætning
331,78 t DKK
Omsætning
4,76 mio.
EBIT %
-695,17 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
26.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Pressemeddelelse21.11.2025, 05.41

BioStock: Stenocare acquires Canngros

Stenocare
Pressemeddelelse19.11.2025, 18.56

STENOCARE share analyst's comments on the CannGros acquisition

Stenocare
Selskabsmeddelelse18.11.2025, 08.59

STENOCARE: Correction of total shares issued and total nominal share capital:

Stenocare

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse17.11.2025, 16.56

STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

Stenocare
Selskabsmeddelelse17.11.2025, 16.01

STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

Stenocare
Selskabsmeddelelse22.10.2025, 06.00

STENOCARE: Interim report third quarter 2025

Stenocare
Selskabsmeddelelse27.8.2025, 19.30

Trading in STENOCARE shares by closely related party to board member

Stenocare
Selskabsmeddelelse21.8.2025, 06.00

STENOCARE: Interim report second quarter 2025

Stenocare
Eksterne analyser19.5.2025, 08.05

STENOCARE: Time to Capitalize on STENOCARE 3.0 - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum oil, which Analyst Group sees as an important...

Stenocare
Selskabsmeddelelse15.5.2025, 09.36

Communiqué from the Annual General Meeting of STENOCARE

Stenocare
Eksterne analyser9.5.2025, 05.25

Analyst Group Comment on STENOCARE's Q1-report

STENOCARE A/S (STENOCARE or the “Company”) published on May 8th the Company’s Q1-report for 2025.

Stenocare
Selskabsmeddelelse8.5.2025, 06.00

STENOCARE: Interim report first quarter 2025

Stenocare
Pressemeddelelse2.5.2025, 12.35

Medical Cannabis Made Permanent in Denmark: Major Milestone for Patients and STENOCARE

Stenocare
Selskabsmeddelelse22.4.2025, 13.01

Notice to Annual General Meeting in STENOCARE A/S

Stenocare
Eksterne analyser4.4.2025, 07.20

Analyst Group Comment on STENOCARE ASTRUM 10-10 Oil Being Approved for Reimbursement in Germany

On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for reimbursement in Germany through major health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible ...

Stenocare
Pressemeddelelse3.4.2025, 06.00

STENOCARE ASTRUM 10-10 Oil Product Approved for Reimbursement in Germany

Stenocare
Pressemeddelelse31.3.2025, 06.00

STENOCARE Begins Sales of New CBD100 Oil Product in Denmark

Stenocare
Pressemeddelelse28.3.2025, 12.25

STENOCARE interview with Proinvestor.com - Annual Report 2024

Stenocare
Selskabsmeddelelse27.3.2025, 07.01

STENOCARE A/S publishes Annual Report 2024

Stenocare
Eksterne analyser6.3.2025, 13.17

STENOCARE: All Focus on Astrum - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum oil, which Analyst Group sees as an important...

Stenocare
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.